FDGCX
Price
$20.59
Change
+$0.18 (+0.88%)
Updated
Jun 6 closing price
Net Assets
1.73B
VTSMX
Price
$143.62
Change
+$1.51 (+1.06%)
Updated
Jun 6 closing price
Net Assets
1.82T
Interact to see
Advertisement

FDGCX vs VTSMX

Header iconFDGCX vs VTSMX Comparison
Open Charts FDGCX vs VTSMXBanner chart's image
Fidelity Advisor Dividend Growth C
Price$20.59
Change+$0.18 (+0.88%)
VolumeN/A
Net Assets1.73B
Vanguard Total Stock Mkt Idx I
Price$143.62
Change+$1.51 (+1.06%)
VolumeN/A
Net Assets1.82T
FDGCX vs VTSMX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FDGCX vs. VTSMX commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FDGCX is a Buy and VTSMX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VTSMX has more cash in the bank: 1.82T vs. FDGCX (1.73B). VTSMX pays higher dividends than FDGCX: VTSMX (1.18) vs FDGCX (0.15). FDGCX was incepted earlier than VTSMX: FDGCX (26 years) vs VTSMX (33 years). FDGCX (1.85) is less costly to investors than VTSMX (0.14). FDGCX is a more actively managed with annual turnover of: 69.00 vs. VTSMX (2.00). FDGCX has a lower initial minimum investment than VTSMX: FDGCX (0) vs VTSMX (3000). VTSMX annual gain was more profitable for investors over the last year : 12.13 vs. FDGCX (1.73). VTSMX return over 5 years is better than : 82.86 vs. FDGCX (45.22).
FDGCXVTSMXFDGCX / VTSMX
Total Expense Ratio1.850.141,321%
Annual Report Gross Expense Ratio1.850.141,321%
Fund Existence26 years33 years-
Gain YTD3.8851.888206%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.73B1.82T0%
Annual Yield % from dividends0.151.1813%
Returns for 1 year1.7312.1314%
Returns for 3 years19.8641.8347%
Returns for 5 years45.2282.8655%
Returns for 10 years23.05182.9113%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CATX3.330.21
+6.57%
Perspective Therapeutics
SMMT20.590.86
+4.36%
Summit Therapeutics
WOR60.230.92
+1.55%
Worthington Enterprises
ACU39.68N/A
N/A
Acme United Corp
CTXR0.85N/A
-0.56%
Citius Pharmaceuticals Inc